Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

Overview of attention for article published in Clinical Ophthalmology, March 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

So far, Altmetric has seen 4 X posts from 2 X users, with an upper bound of 6,451 followers.

#Aflibercept has the same efficacy than #Ranibizumab in treatment of DME but with less number of drug re-injection https://t.co/3cJphezmEw

(1/2) #Aflibercept (#Eylea) vs #Ranibizumab (#Lucentis) para tratamiento Edema Macular Diabético (Cl Oph) https://t.co/S84BhoVGXR

(1/2) #Aflibercept (#Eylea) vs #Ranibizumab (#Lucentis) para tratamiento Edema Macular Diabético (Cl Oph) https://t.co/igg74wvo7T

(1/2) #Aflibercept (#Eylea) vs #Ranibizumab (#Lucentis) for the treatment Diabetic Macular Edema (Cl Oph) https://t.co/3wwrIhlU4a